Prajwal Dhakal

Clinical Assistant Professor

University of Iowa Healthcare

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Prajwal Dhakal is a Clinical Assistant Professor at The University of Iowa Healthcare, United States. His research focuses on acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, with recent publications addressing therapy resistance, patient preferences, and optimizations in cancer care delivery. Additionally, he explores the potential of novel therapeutic approaches and nutritional interventions in oncology.

Articles (19)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Kah Poh Loh

University of Rochester Medical Center

UNITED STATES

View details

Alfred Fisher

Associate Professor and Division Chief

University of Nebraska Medical Center

UNITED STATES

View details

Grerk Sutamtewagul

Clinical Associate Professor

University of Iowa Hospitals and Clinics

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Prajwal Dhakal

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting

Diet and Nutritional Supplementation in Patients With Cancer: Is More Necessarily Better?

Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19

Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?

Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients

Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia

Preferences of Patients with Acute Myeloid Leukemia and Other Myeloid Malignancies on Cancer Treatment: Effect of Patient- and Treatment-Characteristics?

Therapy preferences of patients with cancer.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States

Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study

Association of insurance types and outcomes in acute promyelocytic leukemia

Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis

Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?

Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?

Development and validation of the Therapy Preference Scale to understand patients´ systemic cancer treatment preferences.

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.

Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.

Collaborators (3)

Kah Poh Loh

Alfred Fisher

Grerk Sutamtewagul

Make your next move.